- Home
- FMY vs RFL Comparison
FMY vs RFL Comparison
Compare FMY & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- RFL
- Stock Information
- Founded
- FMY 2005
- RFL 2017
- Country
- FMY United States
- RFL United States
- Employees
- FMY N/A
- RFL N/A
- Industry
- FMY Finance/Investors Services
- RFL Real Estate
- Sector
- FMY Finance
- RFL Finance
- Exchange
- FMY Nasdaq
- RFL Nasdaq
- Market Cap
- FMY 52.7M
- RFL 48.4M
- IPO Year
- FMY N/A
- RFL N/A
- Fundamental
- Price
- FMY $12.38
- RFL $2.00
- Analyst Decision
- FMY
- RFL
- Analyst Count
- FMY 0
- RFL 0
- Target Price
- FMY N/A
- RFL N/A
- AVG Volume (30 Days)
- FMY 10.1K
- RFL 47.3K
- Earning Date
- FMY 01-01-0001
- RFL 10-28-2024
- Dividend Yield
- FMY 6.98%
- RFL N/A
- EPS Growth
- FMY N/A
- RFL N/A
- EPS
- FMY N/A
- RFL N/A
- Revenue
- FMY N/A
- RFL $540,000.00
- Revenue This Year
- FMY N/A
- RFL N/A
- Revenue Next Year
- FMY N/A
- RFL N/A
- P/E Ratio
- FMY N/A
- RFL N/A
- Revenue Growth
- FMY N/A
- RFL 92.86
- 52 Week Low
- FMY $10.71
- RFL $1.29
- 52 Week High
- FMY $12.17
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- FMY 47.25
- RFL 74.68
- Support Level
- FMY $12.40
- RFL $1.65
- Resistance Level
- FMY $12.52
- RFL $1.94
- Average True Range (ATR)
- FMY 0.15
- RFL 0.10
- MACD
- FMY -0.02
- RFL 0.02
- Stochastic Oscillator
- FMY 12.37
- RFL 100.00
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.